Andere Sprachen XOMA Corporation

Aktien

A2ATUH

US98419J2069

XOMA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
25,36 ^USD	-1,09 %		+3,13 %	+37,08 %

03.04.	Die XOMA Corporation (NasdaqGM:XOMA) hat die Übernahme von Kinnate Biopharma Inc. (NasdaqGS:KNTE) abgeschlossen.	CI
08.03.	XOMA Corporation meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	25.04.
XOMA : Acquisition/Asset Disposal - Form 8-K	03.04.
XOMA Corporation Announces Closing of Tender Offer	03.04.
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	03.04.
XOMA Declares Quarterly Preferred Stock Dividends	21.03.
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	19.03.
Xoma: Q4 Earnings Snapshot	08.03.
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	08.03.
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	08.03.
XOMA to Present at Upcoming Investor Conferences in March	28.02.
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	19.02.
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA	16.02.
Sector Update: Health Care Stocks Advance Friday Afternoon	16.02.
XOMA Agrees to Acquire Kinnate Biopharma	16.02.
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right	16.02.
XOMA Corporation entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. for approximately $120 million.	16.02.
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition	19.01.
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million	18.01.
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition	18.01.
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.	18.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen XOMA Corporation

Aktien

A2ATUH

US98419J2069

XOMA

Andere Sprachen

Filter